Novo Nordisk A/S (NYSE:NVO) Shares Sold by JNBA Financial Advisors

JNBA Financial Advisors cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 47.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,187 shares of the company’s stock after selling 2,000 shares during the quarter. JNBA Financial Advisors’ holdings in Novo Nordisk A/S were worth $260,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. 1620 Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth approximately $25,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. Gilliland Jeter Wealth Management LLC increased its stake in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. raised its position in Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on NVO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $105.35 on Thursday. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The firm has a market capitalization of $472.76 billion, a price-to-earnings ratio of 36.08, a price-to-earnings-growth ratio of 1.43 and a beta of 0.42. The business’s 50 day simple moving average is $122.65 and its 200-day simple moving average is $130.59. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The firm had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.